Skip to main content
v2026.11,986 entries · CC-BY 4.0

FDA Debarment List: What It Covers and How to Check It

What the FDA debarment list covers under 21 USC 335a, how to read its notations and terms, and how to screen names against it.

Written and maintained by CASRAI Editorial Board

Published

On this page

The FDA debarment list is the public list of firms and individuals that FDA has debarred under section 306 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 335 and 335a) from taking part in the drug product application process. FDA publishes it as web tables with downloadable Excel files, and anyone who sponsors, conducts or staffs work that supports a drug application can search it by name. This guide explains what the list covers, how to read its notations, what the statute requires of applicants, and which other lists are easily confused with it. Everything below is as described on the official FDA pages and in 21 U.S.C. 335a on 2026-11-13.

What it is and who runs it

The page titled FDA Debarment List (Drug Product Applications) lists firms and persons currently debarred under section 306(a) or (b) of the FD&C Act, as published in the Federal Register. FDA compiles it under 21 U.S.C. 335a(e), which requires the Secretary to publish debarments in the Federal Register and to keep a public list that is updated no less often than quarterly. On 2026-11-13 the page showed content current as of 10/02/2026, with the firms table reading "None as of this date" and a table of persons showing last name, first and middle name, effective date, term and Federal Register citation.

A second page, FDA Debarment List (Drug Imports), covers persons debarred under section 306(b)(3)(C) or (D) (21 U.S.C. 335(b)(3)(C) and (D)), also compiled under 335a(e). It was current as of 09/25/2026 when read, with no firms listed. FDA also publishes a separate expired-debarment list for drug product applications, so a name that is missing from the current list may still appear in the expired list.

The lists themselves do not state a fixed update schedule beyond the statute’s quarterly floor, so the "current as of" date at the top of each page, not the date you visit, is the date your search actually reflects.

Who can be debarred

Section 335a separates mandatory from permissive debarment.

  • Mandatory, entities (335a(a)(1)): a firm is debarred after a felony conviction tied to an abbreviated drug application.
  • Mandatory, individuals (335a(a)(2)): a person convicted of a felony tied to the development or approval of a drug product, or to its regulation, is barred from providing services in any capacity to a drug applicant.
  • Permissive (335a(b)): the Secretary may act on the agency’s own initiative or on petition. Some of the grounds require a finding that the conduct undermines the process for the regulation of drugs.

No debarment takes effect by list entry alone. Under 335a(i) the action is taken only by order on the record after an agency hearing, and 335a(j) provides for judicial review in the D.C. Circuit or the circuit where the person resides, generally within 60 days. The list is the public record of orders already made, not a place where FDA decides anything.

How to read the entries and notations

The legend on the FDA page matters because the same table mixes different kinds of action. As described on the page:

  • A caret (^) marks a mandatory 306(a) debarment, and the term is shown as "Permanent^".
  • A percent sign (%) marks a permissive 306(b) debarment with a fixed term, for example "5 years%".
  • An asterisk (*) means a hearing was requested and denied; a hash (#) means the person acquiesced; "aka" and "NMI" are also defined in the legend.
  • On the drug imports list, a lower-case "p" marks a pattern of importing or offering for import.

Terms follow the statute. Under 335a(c), an entity debarred under (a)(1) is debarred for not less than one nor more than ten years; an individual debarred under (a)(2) is debarred permanently; and debarments under (b)(2) or (b)(3) run for not more than five years. The Secretary also may not accept or review abbreviated applications submitted by or with the assistance of a debarred entity. Debarments from before 1994 are not shown online, and Federal Register notices before 1995 are available as PDFs through govinfo, according to the FDA page.

What the statute requires of applicants and sponsors

The compliance duty is in 335a(k): a drug application must include a certification that the applicant did not and will not use, in any capacity, the services of any person debarred under the section. Abbreviated applications must also list convictions of the kinds covered by the section in the prior five years. "In any capacity" is the operative phrase for staffing: it is not limited to the applicant’s own employees, and it is the reason sponsors, contract research organisations and sites screen the people they bring onto a development programme.

Temporary denial of approval (up to 18 months) and suspension of distribution, covered in 335a(f) to (h), are separate actions from debarment and do not appear on this list.

How to check a name: compliance steps

  1. Open the right list. Use the Drug Product Applications list for section 306(a) and most 306(b) debarments, and the Drug Imports list for 306(b)(3)(C) and (D). Check the expired list too if your question is about past service.
  2. Record the "current as of" date shown on each page, together with the date you searched and the name variants you used, including middle names and any "aka" entries.
  3. Match carefully. The FDA page warns that some names are shared, so a surname match is not a finding. Compare first and middle names, and the Federal Register citation, before concluding anything about a real person.
  4. Escalate matches through your compliance office. Questions about a listing can go to FDA at [email protected] or 1-888-INFO-FDA, the contacts given on the page.
  5. Keep the screening record with the application or study file, because the certification in 335a(k) is a statement about services used, which you may later need to support.
  6. Screen the neighbouring lists separately (see the table below); a clean result here says nothing about them.

Typical process phases behind an entry

An entry usually reflects a sequence rather than a single event, described here without dates because each case differs. A conviction or a finding of conduct triggers a proposal; the person receives notice and a hearing on the record under 335a(i); a final order is issued; the debarment is published in the Federal Register; and FDA adds the person to the list, with the Federal Register citation in the table. After that, a debarred person may apply for termination under 335a(d), and the Secretary decides such an application within 180 days. Permanent debarments are excluded from ordinary termination. A person whose debarment ends moves from the current list to the expired list.

Common mistakes

  • Treating one list as all exclusion screening. The FDA list, FDA’s clinical investigator disqualification list, SAM.gov and the OIG exclusion list are separate lists with separate legal bases. See the table below and the CASRAI guide on SAM and LEIE debarment and exclusion screening.
  • Confusing debarment with disqualification. Clinical investigator disqualification under 21 CFR 312.70 follows a finding of repeated or deliberate noncompliance or false reporting, runs through a different process, and is listed on a different FDA page.
  • Matching on surname alone. FDA itself warns that names are shared.
  • Reading an empty firms table as an empty list. The firms table can read "None" while the persons table is long.
  • Searching only the current list when the question concerns an earlier period.
  • Assuming a screening frequency. The statute sets a quarterly publication floor for FDA, not a screening interval for sponsors; follow your own policy and your sponsor’s contract terms.

The data table at the end of this page compares the FDA actions described above. The lists below sit alongside them in a research compliance programme:

List or action Maintained by What it covers CASRAI guide
FDA debarment lists (this page) FDA Persons and firms debarred under FD&C Act section 306 from drug product applications or drug importing This guide
FDA clinical investigator disqualification FDA Investigators who repeatedly or deliberately failed to comply with IND regulations or submitted false information (21 CFR 312.70) Exclusion screening for clinical research staff
SAM.gov exclusions General Services Administration Parties debarred, suspended or excluded from federal awards and contracts (2 CFR Part 180) SAM.gov debarment and suspension verification
Research integrity and award-history checks Federal awarding agencies Suspension, debarment and integrity records relevant to federal awards FAPIIS and integrity checks
OIG exclusion screening for suppliers HHS Office of Inspector General Individuals and entities excluded from federal health care programs OIG exclusion check for medical supply vendors

Frequently asked questions

What is the FDA debarment list?

It is FDA’s public list of firms and persons debarred under section 306 of the FD&C Act, compiled under 21 U.S.C. 335a(e) from orders published in the Federal Register.

How often is the FDA debarment list updated?

The statute requires the list to be updated no less often than quarterly. The FDA page does not state a more specific schedule and shows a "current as of" date.

Is a debarred person always barred permanently?

No. Individuals debarred under 335a(a)(2) are debarred permanently, while entity debarments under (a)(1) run one to ten years and permissive debarments under (b)(2) or (b)(3) run up to five years.

Is the FDA debarment list the same as the OIG exclusion list or SAM.gov?

No. Each is maintained by a different agency under a different legal authority, so each needs its own search.

Can a debarment end?

A person may apply for termination under 335a(d), with a decision due within 180 days; permanent debarments are excluded from ordinary termination. Ended debarments move to FDA’s expired list.

Who should ask FDA about a listing?

The page gives [email protected] and 1-888-INFO-FDA as contacts. Your institution’s compliance office decides what to do with a match.

Sources

Programs and lists change; check the official pages for the current position.

Data: FDA drug-related debarment and disqualification actions: legal basis, scope and duration

Compares four FDA debarment categories and clinical investigator disqualification by legal basis, who they apply to and duration, compiled from the FDA debarment list pages, 21 U.S.C. 335a and 21 CFR 312.70 as read on 2026-11-13.

Coverage: United States.

FDA drug-related debarment and disqualification actions: legal basis, scope and duration
ActionLegal basisApplies toDurationWhere listed
Mandatory debarment, entityFD&C Act 306(a)(1); 21 U.S.C. 335a(a)(1)Firm convicted of a felony tied to an abbreviated drug applicationNot less than 1 and not more than 10 yearsFDA Debarment List (Drug Product Applications)
Mandatory debarment, individualFD&C Act 306(a)(2); 21 U.S.C. 335a(a)(2)Person convicted of a felony tied to drug development, approval or regulationPermanentFDA Debarment List (Drug Product Applications)
Permissive debarmentFD&C Act 306(b); 21 U.S.C. 335a(b)Persons or firms debarred on the Secretary's initiative or petitionNot more than 5 yearsFDA Debarment List (Drug Product Applications)
Drug imports debarmentFD&C Act 306(b)(3)(C) or (D); 21 U.S.C. 335(b)(3)Persons debarred under the imports provisionsNot more than 5 years under 335a(c) for (b)(3)FDA Debarment List (Drug Imports)
Clinical investigator disqualification21 CFR 312.70Investigator who repeatedly or deliberately failed to comply or submitted false informationUntil reinstated on adequate assurancesFDA Clinical Investigators - Disqualification Proceedings page

Sources

Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · full access

Ask about FDA Debarment List: What It Covers and How to Check It

Full access: large monthly usage, up to 10 source passages behind each answer, and MCP and API access for Claude Code, Codex and other CLIs. Cancel any time.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →